Vimal Ramjee Joins Cardio Diagnostics Holdings as Strategic Advisor

Cardio Diagnostics Holdings Inc. has appointed cardiologist Vimal Ramjee, M.D. as a strategic advisor. Ramjee serves as the national co-chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is also a member of the American Heart Association Board of Directors.
 
Ramjee has a wealth of experience and proven track record in clinical practice, innovation and research. “I am thrilled to welcome Dr. Ramjee to our team. His expertise in cardiovascular medicine will be pivotal in advancing our innovation and research efforts. His guidance will be crucial in forging new collaborations and enhancing our impact on cardiac care globally,” Cardio Diagnostics Co-Founder/CEO Meesha Dogan, Ph.D.
 
Ramjee’s career in cardiovascular medicine is marked by significant academic and professional achievements. He is a cardiologist and health innovation leader working at the intersection of medicine, digital health technologies, and artificial intelligence algorithms. He has dedicated his career to improving health outcomes for people with cardiovascular disease. He earned his bachelor of science degree from Emory University, followed by his medical degree from the Mount Sinai School of Medicine in New York. After medical school, Ramjee completed his residency in internal medicine at Emory Hospital in Atlanta. He then pursued a fellowship in cardiovascular disease and advanced cardiovascular imaging and translational research at the Hospital of the University of Pennsylvania in Philadelphia.
 
Ramjee holds seven active board certifications in cardiology, AI in medicine, internal medicine, echocardiography, cardiovascular CT, nuclear medicine, and culinary medicine. His contributions to the scientific field have been recognized with accolades from the American College of Cardiology (ACC), NIH, Northwestern University, and American College of Physicians (ACP). His work has been published in various peer-reviewed journals, including JACC, JASE, The Journal of Clinical Investigation, Resuscitation, Echocardiography, Journal of Vascular Surgery, and Annals of the New York Academy of Science, among others.
 
“I am excited to join Cardio Diagnostics and contribute to the company’s mission of improving cardiovascular health,” Ramjee stated. “I am confident that my experience and expertise will be valuable as the company continues to grow and drive new innovations in cardiac care.”
 
As a Strategic Advisor, Ramjee will partner with Cardio Diagnostics’ management team on several initiatives, including new research studies and capitalizing on emerging opportunities. Ramjee will also work to raise awareness of Cardio Diagnostics’ technologies and their potential to improve patient care. 
 
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated genetic-epigenetic engine (core technology) to help improve the prevention, detection, and treatment of cardiovascular disease.